What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to formally announce and report that Regeneron Pharmaceuticals, Inc., along with its partner Sanofi-aventis, has issued a press release providing an update on the clinical development program for aflibercept (VEGF Trap), specifically including results from a Phase 2 study in advanced ovarian cancer.

What is aflibercept (VEGF Trap)?

Aflibercept, also known as VEGF Trap, is an investigational drug developed by Regeneron Pharmaceuticals. It is designed to inhibit the growth of new blood vessels that tumors need to grow and survive.

Where can I find the detailed results of the Phase 2 study?

The detailed results of the Phase 2 study in advanced ovarian cancer are contained within the press release issued by Regeneron Pharmaceuticals and Sanofi-aventis on May 21, 2008. This press release is included as Exhibit 99.1 to this 8-K filing and is incorporated by reference.

What is the significance of this announcement for Regeneron investors?

For Regeneron investors, this announcement signifies progress in the clinical development of a key pipeline asset, aflibercept. Updates on clinical trial results, especially from partnered programs, are crucial for assessing the potential future value and commercialization prospects of the company's drug candidates.

REGN 8-K SEC Disclosure

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K report on May 21, 2008, to announce an update on the clinical development of its investigational drug, aflibercept (VEGF Trap). This update, provided in conjunction with partner Sanofi-aventis, includes results from a Phase 2 study evaluating aflibercept in patients with advanced ovarian cancer. Investors should note that this filing primarily serves as a notification of the release of this information. The actual clinical data and its implications would be detailed within the accompanying press release (Exhibit 99.1), which is incorporated by reference. The focus of this report is on the disclosure of progress in a significant drug development program, highlighting ongoing research and potential future milestones for Regeneron and its collaborator.

Key Highlights

1Regeneron Pharmaceuticals, Inc. (REGN) filed a Form 8-K on May 21, 2008.
2The filing announces an update on the clinical development of aflibercept (VEGF Trap).
3The update is in collaboration with partner Sanofi-aventis.
4Results from a Phase 2 study in advanced ovarian cancer are being provided.
5The press release containing the detailed update is attached as Exhibit 99.1.
6This filing serves to officially report the dissemination of this clinical development information.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Corporate Update (May 21, 2008)

Summary

Key Highlights

Frequently Asked Questions